These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 2973594)

  • 1. [Treatment of infection in granulopenic patients. Lessons from international studies].
    Beytout J; Travade P; Petit MF
    Presse Med; 1988 Oct; 17(37):1950-3. PubMed ID: 2973594
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monotherapy for empirical management of febrile neutropenic patients.
    Rubin M; Pizzo PA
    NCI Monogr; 1990; (9):111-6. PubMed ID: 2160613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using teicoplanin for empiric therapy of febrile neutropenic patients with haematological malignancies.
    Menichetti F; Del Favero A; Bucaneve G; Aversa F; Fiorio M
    Br J Haematol; 1990 Dec; 76 Suppl 2():45-8. PubMed ID: 2149052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ceftazidime for the treatment of infections in neutropenic children].
    Leverger G; Arlet G; Bancillon A; Schaison G
    Presse Med; 1988 Oct; 17(37):1974-6. PubMed ID: 2973600
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination and single-agent empirical antibacterial therapy for febrile cancer patients with neutropenia and mucositis.
    Shenep JL
    NCI Monogr; 1990; (9):117-22. PubMed ID: 2342588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of antibiotic therapy for infection in neutropenic patients: studies at M. D. Anderson Hospital.
    Bodey GP
    Rev Infect Dis; 1989; 11 Suppl 7():S1582-90. PubMed ID: 2690296
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical guidelines for the management of neutropenic patients with unexplained fever in Japan: validation by the Japan Febrile Neutropenia Study Group.
    Tamura K
    Int J Antimicrob Agents; 2005 Dec; 26 Suppl 2():S123-7; discussion S133-40. PubMed ID: 16249072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beta-lactam regimens for the febrile neutropenic patient.
    Bodey GP; Fainstein V; Elting LS; Anaissie E; Rolston K; Khardori N; Kantarjian H; Plager C; Murphy WK; Holmes F
    Cancer; 1990 Jan; 65(1):9-16. PubMed ID: 2403484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Probabilistic treatment with ceftazidime of infections in neutropenic patients].
    Schaison G; Leverger G; Arlet G
    Presse Med; 1988 Oct; 17(37):1988-90. PubMed ID: 2973604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The results of a randomized trial of empirical antibiotic treatment in febrile neutropenic patients with four beta-lactam/aminoglycoside combinations.
    Hann I; Noone P; Prentice HG; Sage R; Blacklock H; Stirling L; Gray R; Corringham R; Boesen E; Mohiuddin J
    J Antimicrob Chemother; 1983 May; 11 Suppl C():57-63. PubMed ID: 6352605
    [No Abstract]   [Full Text] [Related]  

  • 11. Empirical antibiotics for febrile neutropenic cancer patients.
    Hathorn JW
    Eur J Cancer Clin Oncol; 1989; 25 Suppl 2():S43-51. PubMed ID: 2693109
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Empiric antimicrobial therapy for febrile granulocytopenic cancer patients: lessons from four EORTC trials.
    Klastersky J; Zinner SH; Calandra T; Gaya H; Glauser MP; Meunier F; Rossi M; Schimpff SC; Tattersall M; Viscoli C
    Eur J Cancer Clin Oncol; 1988; 24 Suppl 1():S35-45. PubMed ID: 3280326
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-infective strategies in neutropenic patients.
    Maertens J; Boogaerts MA
    Acta Clin Belg; 1998 Jun; 53(3):168-77. PubMed ID: 9701851
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controversies in the management of febrile neutropenic cancer patients.
    Rubin M; Hathorn JW; Pizzo PA
    Cancer Invest; 1988; 6(2):167-84. PubMed ID: 3132310
    [No Abstract]   [Full Text] [Related]  

  • 15. [Prospective and comparative study of 2 antibiotic therapy protocols in 66 febrile neutropenic patients. Ceftazidime-vancomycin versus ticarcillin-vancomycin-amikacin].
    Brion JP; Bru JP; Michallet M; Corron B; Fauconnier J
    Presse Med; 1988 Oct; 17(37):1964-7. PubMed ID: 2973597
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Imipenem/cilastatin versus ceftazidime-amikacin in the treatment of febrile neutropenic patients].
    Pérez C; Sirham M; Labarca J; Grebe G; Lira P; Oliva J; Duhalde M; Ocqueteau M; Acuña G
    Rev Med Chil; 1995 Mar; 123(3):312-20. PubMed ID: 8525170
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of gram-positive therapy in the neutropenic patient.
    Menichetti F; Del Favero A
    J Antimicrob Chemother; 1991 Apr; 27 Suppl B():51-60. PubMed ID: 1829077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro evaluation of newer beta-lactam antibiotics against gram negative bacilli isolated from neutropenic patients.
    Ebenezer S; Lalitha MK; Jesudason MV; Chandy M
    Indian J Cancer; 1994 Mar; 31(1):23-6. PubMed ID: 8063332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review of amikacin usage in the EORTC trials.
    Zinner SH
    Am J Med; 1985 Jul; 79(1A):17-20. PubMed ID: 3895903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylaxis of bacterial infections with oral antibiotics in neutropenic patients. Lessons from the last two EORTC trials and prospects for the future.
    Zinner SH
    Schweiz Med Wochenschr Suppl; 1983; 14():7-14. PubMed ID: 6361995
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.